Emre Aldinc

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis

Simina Ticau, Gautham Sridharan, Shira Tsour et al. · Neurology · 2020 · 101 citations · Full text

Life Sciences, Biochemistry, Neurology +16

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Alejandra González‐Duarte, John L. Berk, Dianna Quan et al. · Journal of Neurology · 2019 · 61 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys

Rayaz A. Malik, Emre Aldinc, Siew-Pheng Chan et al. · Advances in Therapy · 2017 · 58 citations · Full text

Medicine, Family Medicine, Clinical Medicine +14

Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry

Margaret M. Parker, Scott M. Damrauer, Catherine Tcheandjieu et al. · Scientific Reports · 2021 · 34 citations · Full text

Medicine, Genetics, Molecular Genetics +17